摘要
目的探究布托啡诺复合帕瑞昔布钠用于悬雍垂腭咽成形术(UPPP)后患者静脉自控镇痛(PCIA)中的效果。方法选取2021年10月至2023年5月我院收治的拟行UPPP的患者80例,按照随机数字表法分为帕瑞昔布钠组(D组)、布托啡诺小剂量组(B1组)、布托啡诺中剂量组(B2组)、布托啡诺大剂量组(B3组),每组20例。D组患者使用40 mg帕瑞昔布钠+0.9%氯化钠注射液镇痛;B1组、B2组、B3组患者在D组基础上分别复合3.0μg·kg^(-1)·h^(-1)、4.0μg·kg^(-1)·h^(-1)、5.0μg·kg^(-1)·h^(-1)布托啡诺进行PCIA。比较各组患者PCIA前及PCIA后2 h、12 h、24 h、48 h的心率和平均动脉压;比较各组患者在PCIA后2 h、12 h、24 h、48 h的疼痛视觉模拟评分法(VAS)评分、Ramsay评分;记录PCIA按压次数及术后不良反应发生情况。结果PCIA前及PCIA后2 h、12 h、24 h、48 h,各组患者的心率和平均动脉压比较,差异均无统计学意义(P>0.05)。与D组相比,PCIA后2 h、12 h、24 h、48 h,B1、B2、B3组患者的VAS评分显著降低(P<0.05),且布托啡诺剂量越高,VAS评分越低(P<0.05)。与D组相比,PCIA后2 h、12 h、24 h、48 h,B1、B2、B3组患者的Ramsay评分显著升高(P<0.05),且布托啡诺剂量越高,Ramsay评分越高(P<0.05)。B3组患者不良反应总发生率显著高于D组、B1组、B2组(P<0.05);与D组相比,B1组、B2组、B3组患者的PCIA按压次数显著减少(P<0.05),且布托啡诺剂量越高,PCIA按压次数越少(P<0.05)。结论布托啡诺复合帕瑞昔布钠用于UPPP后PCIA的效果较好,且复合4.0μg·kg^(-1)·h^(-1)的帕瑞昔布钠镇痛效果更显著,安全性更高。
Objective To investigate the effect of butorphanol combined with parecoxib sodium on patient-controlled intravenous analgesia(PCIA)after uvulo-palato-pharyngo-plasty(UPPP).Methods Eighty patients who were admitted to our hospital from October 2021 to May 2023 and planned to receive UPPP were collected,and they were randomly assigned to the paroxicib sodium group(D group),the butorphanol low-dose group(B1 group),the butorphanol medium dose group(B2 group),and the butorphanol high-dose group(B3 group),with 20 cases in each group.Patients in the D group received 40 mg of paroxycoxib sodium with 0.9%sodium chloride injection for analgesia,and patients in the B1 group,the B2 group,and the B3 group were combined with 3.0μg·kg^(-1)·h^(-1),4.0μg·kg^(-1)·h^(-1),and 5.0μg·kg^(-1)·h^(-1)of butorphanol respectively on the basis of D group.The heart rate and mean arterial pressure before PCIA and 2 hours,12 hours,24 hours,and 48 hours after PCIA were compared among the four groups;the pain visual analogue scale(VAS)score,Ramsay score 2 hours,12 hours,24 hours,and 48 hours after PCIA were compared among the four groups;the number of PCIA compression,and incidence of adverse reactions were recorded.Results There was no statistically significant difference in the heart rate or mean arterial pressure before PCIA and 2 hours,12 hours,24 hours,and 48 hours after PCIA among the four groups(P>0.05).Compared with the D group,the VAS scores 2 hours,12 hours,24 hours,and 48 hours after PCIA of the B1,B2,and B3 groups significantly decreased(P<0.05),and the higher the dose of butorphanol,the lower the VAS score(P<0.05).Compared with the D group,the Ramsay scores 2 hours,12 hours,24 hours,and 48 hours after PCIA of the B1,B2,and B3 groups obviously increased(P<0.05),and the higher the dose of butorphanol,the higher the Ramsay score(P<0.05).The total incidence of adverse reactions in the B3 group was obviously higher than that in the D group,the B1 group,and the B2 group(P<0.05).Compared with the D group,patients in the B1,B2,and
作者
熊浪
魏媛媛
杨志军
XIONG Lang;WEI Yuan-yuan;YANG Zhi-jun(Department of Surgical Anesthesiology,Ezhou Central Hospital,Ezhou Hubei 436000,China;Department of Otolaryngology,Ezhou Central Hospital,Ezhou Hubei 436000,China)
出处
《局解手术学杂志》
2024年第11期941-944,共4页
Journal of Regional Anatomy and Operative Surgery
基金
鄂州市中心医院关于2022年度院级科研项目计划(〔2022〕17号-7)。
关键词
布托啡诺
帕瑞昔布钠
悬雍垂腭咽成形术
患者静脉自控镇痛
效果
butorphanol
paroxicib sodium
uvulo-palato-pharyngo-plasty
patient-controlled intravenous analgesia
effect
